-
Innovation Ranking
Innovation Ranking – IVERIC bio Inc
IVERIC bio Inc (IVERIC bio), formerly known as Ophthotech Corp, is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt disease. It provides Fovista, an anti-platelet-derived growth factor (PDGF). IVERIC bio offers gene therapy research programs, dry age-related macular degeneration and ophthalmic orphan programs. The company seeks to collaborate with companies and academic institutions to develop gene therapy product...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024
Empower your strategies with our Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis,...
-
Product Insights
NewLeber Congenital Amaurosis (LCA) – Drugs In Development, 2024
Empower your strategies with our Leber Congenital Amaurosis (LCA) – Drugs In Development, 2024 report and make more profitable business decisions. Leber congenital amaurosis (LCA) is a genetic eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. The Leber...
-
Product Insights
NewUsher Syndrome – Drugs In Development, 2024
Empower your strategies with our Usher Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration; prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids, and Vitamin A supplementation. The Usher Syndrome drugs in development market research...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Fidanacogene elaparvovec
Empower your strategies with our Net Present Value Model: Pfizer Inc's Fidanacogene elaparvovec report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:TPST-1495 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt...